Isradipine, a new and potent antihypertensive dihydropyridine calcium antagonist, was evaluated in 132 patients (66.7% females and 33.3% males) withe the clinical diagnosis of mild to moderate hypertension, in an open multicenter study that took place in the hypertension, in an open multicenter study that took place in the hypertension clinics of several peruvian hospitals. The protocol include a wash out or diagnosis confirmation period of two weeks followed by 12 weeks of treatment with 2.5 mg isradipine twice daily.  The patients mean age was 56.7 (+-6.3), weight 66.9 kg (+- 11.0) and height 160 (+- 9.0). 30.3% of the patients had associated diseases, 86.4% had been previously treated for hypertension and 85.8% had a clinical diagnosis of arterial hypertension for more than one year.  After 90 days of treatment there was a mean decrease of 28.8 mmHg in the diastolic arterial...

Isradipine, a new and potent antihypertensive dihydropyridine calcium antagonist, was evaluated in 132 patients (66.7% females and 33.3% males) withe the clinical diagnosis of mild to moderate hypertension, in an open multicenter study that took place in the hypertension, in an open multicenter study that took place in the hypertension clinics of several peruvian hospitals. The protocol include a wash out or diagnosis confirmation period of two weeks followed by 12 weeks of treatment with 2.5 mg isradipine twice daily.  The patients mean age was 56.7 (+-6.3), weight 66.9 kg (+- 11.0) and height 160 (+- 9.0). 30.3% of the patients had associated diseases, 86.4% had been previously treated for hypertension and 85.8% had a clinical diagnosis of arterial hypertension for more than one year.  After 90 days of treatment there was a mean decrease of 28.8 mmHg in the diastolic arterial...